Percutaneous Coronary Intervention as a Trigger for Stroke - 18/04/17
, Imre Janszky, MD, PhD a, b, Inger J. Bakken, PhD c, Hanne Ellekjær, MD, PhD d, Hild Fjærtoft, PhD e, f, Siri E. Håberg, MD, PhD c, Kaare H. Bønaa, MD, PhD a, g, hAbstract |
Percutaneous coronary intervention (PCI) is a plausible triggering factor for stroke, yet the magnitude of this excess risk remains unclear. This study aimed to quantify the transient change in risk of stroke for up to 12 weeks after PCI. We applied the case-crossover method, using data from the Norwegian Patient Register on all hospitalizations in Norway in the period of 2008 to 2014. The relative risk (RR) of ischemic stroke was highest during the first 2 days after PCI (RR 17.5, 95% confidence interval [CI] 4.2 to 72.8) and decreased gradually during the following weeks. The corresponding RR was 2.0 (95% CI 1.2 to 3.3) 4 to 8 weeks after PCI. The RR for women was more than twice as high as for men during the first 4 postprocedural weeks, RR 10.5 (95% CI 3.8 to 29.3) and 4.4 (95% CI 2.7 to 7.2), respectively. Our results were compatible with an increased RR of hemorrhagic stroke 4 to 8 weeks after PCI, but the events were few and the estimates were very imprecise, RR 3.0 (95% CI 0.8 to 11.1). The present study offers new knowledge about PCI as a trigger for stroke. Our estimates indicated a substantially increased risk of ischemic stroke during the first 2 days after PCI. The RR then decreased gradually but stayed elevated for 8 weeks. Increased awareness of this vulnerable period after PCI in clinicians and patients could contribute to earlier detection and treatment for patients suffering a postprocedural stroke.
Le texte complet de cet article est disponible en PDF.Plan
| This work was supported by the Liaison Committee between the Central Norway Regional Health Authority, the Norwegian Research Council, and the Norwegian University of Science and Technology, Trondheim, Norway. |
|
| See page 38 for disclosure information. |
Vol 119 - N° 1
P. 35-39 - janvier 2017 Retour au numéro
Article précédent
- Causes and Predictors of Death in Patients With Coronary Heart Disease (from the Heart and Soul Study)
- Elizabeth Y. Wang, Jeffrey Dixson, Nelson B. Schiller, Mary A. Whooley
- Effect of Alirocumab on Lipoprotein(a) Over ?1.5 Years (from the Phase 3 ODYSSEY Program)
- Daniel Gaudet, Gerald F. Watts, Jennifer G. Robinson, Pascal Minini, William J. Sasiela, Jay Edelberg, Michael J. Louie, Frederick J. Raal
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?